Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202)

被引：0
|
作者：
Toshirou Nishida
Kuniaki Shirao
Akira Sawaki
Masato Koseki
Takeshi Okamura
Atsushi Ohtsu
Toshiro Sugiyama
Kunihisa Miyakawa
Seiichi Hirota
机构：
[1] Osaka University Graduate School of Medicine,Department of Surgery
[2] National Cancer Center Hospital,Department of Medical Oncology
[3] Aichi Cancer Center Hospital,Department of Gastroenterology
[4] National Hospital Organization Kure Medical Center,Department of Surgery
[5] National Kyushu Cancer Center,Department of Gastroenterological Surgery
[6] National Cancer Center Hospital East,Division of Gastrointestinal Oncology/Digestive Endoscopy
[7] Hokkaido University Graduate School of Medicine,Department of Gastroenterology
[8] National Cancer Center Hospital,Diagnostic Radiology Division
[9] Hyogo College of Medicine,Department of Surgical Pathology
来源：
International Journal of Clinical Oncology | 2008年 / 13卷
关键词：
Gastrointestinal stromal tumor; Imatinib; Phase II;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] A phase II study of the KIT inhibitor XL820 in patients with advanced gastrointestinal stromal tumors (GIST) resistant to or intolerant of imatinib and/or sunitinib
    Wagner, A. J.
    Yazji, S.
    Morgan, J. A.
    Choy, E.
    George, S.
    Hohos, M.
    O'Mara, M.
    Demetri, G. D.
    EJC SUPPLEMENTS, 2008, 6 (12): : 67 - 67
  • [32] INTRIGUE: a randomized, open-label, phase 3 study evaluating the efficacy and safety of ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumors previously treated with imatinib
    Bauer, S.
    Jones, R. L.
    Gelderblom, H.
    George, S.
    Schoeffski, P.
    Von Mehren, M.
    Zalcberg, J.
    Kang, Y. K.
    Razak, A. A.
    Trent, J.
    Attia, S.
    Le Cesne, A.
    Su, Y.
    Meade, J.
    Wang, T.
    Sherman, M. L.
    Ruiz-Soto, R.
    Blay, J. Y.
    Heinrich, M. C.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 263 - 263
  • [33] Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study (vol 25, pg 4611, 2019)
    Toulmonde, Maud
    Blay, Jean-Yves
    Bouche, Olivier
    Mir, Olivier
    Penel, Nicolas
    Isambert, Nicolas
    Duffaud, Florence
    Bompas, Emmanuelle
    Esnaud, Thomas
    Boidot, Romain
    Geneste, Damien
    Ghiringhelli, Francois
    Lucchesi, Carlo
    Bellera, Carine A.
    Le Loarer, Francois
    Italiano, Antoine
    CLINICAL CANCER RESEARCH, 2019, 25 (15) : 4859 - 4859
  • [34] Gleevec/Glivec (imatinib mesylate, STI-571) in patients with chronic myeloid leukemia (CML) in myeloid blast crisis: Updated results of a phase II study.
    Sawyers, CL
    Hochhaus, A
    Feldman, E
    Goldman, JM
    Miller, C
    Ottman, OG
    Schiffer, CA
    Talpaz, M
    Guilhot, F
    Niederwieser, D
    Ben-Am, M
    Gathmann, I
    Ford, J
    Druker, BJ
    BLOOD, 2001, 98 (11) : 845A - 845A
  • [35] Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study
    Kang, Hye Jin
    Ryu, Min-Hee
    Kim, Kyoung-Mee
    Park, Young Soo
    Choi, Jene
    Ryoo, Baek-Yeol
    Kim, Woo Ho
    Im, Seock-Ah
    Bang, Yung-Jue
    Park, Se Hoon
    Lee, Jae-Hyuk
    Chung, Ik Joo
    Bae, Han-Ik
    Kim, Jong Gwang
    Lee, Kyung Hee
    Song, Hong Suk
    Kwon, Hyuk-Chan
    Baek, Jin Ho
    Shin, Dong Bok
    Lee, Kyoung Eun
    Kang, Yoon-Koo
    ACTA ONCOLOGICA, 2012, 51 (04) : 528 - 536
  • [36] Phase II Study of Cediranib in Patients with Advanced Gastrointestinal Stromal Tumors or Soft-Tissue Sarcoma
    Judson, Ian
    Scurr, Michelle
    Gardner, Kate
    Barquin, Elizabeth
    Marotti, Marcelo
    Collins, Barbara
    Young, Helen
    Juergensmeier, Juliane M.
    Leahy, Michael
    CLINICAL CANCER RESEARCH, 2014, 20 (13) : 3603 - 3612
  • [37] A prospective multicenter phase II study on the efficacy and safety of dasatinib in the treatment of metastatic gastrointestinal stromal tumors failed by imatinib and sunitinib and analysis of NGS in peripheral blood
    Zhou, Ye
    Zhang, Xinhua
    Wu, Xiaojun
    Zhou, Yongjian
    Zhang, Bo
    Liu, Xiufeng
    Wu, Xin
    Li, Yan
    Shen, Lin
    Li, Jian
    CANCER MEDICINE, 2020, 9 (17): : 6225 - 6233
  • [38] A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors
    Schoffski, P.
    Reichardt, P.
    Blay, J-Y
    Dumez, H.
    Morgan, J. A.
    Ray-Coquard, I.
    Hollaender, N.
    Jappe, A.
    Demetri, G. D.
    ANNALS OF ONCOLOGY, 2010, 21 (10) : 1990 - 1998
  • [39] Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial
    Komatsu, Yoshito
    Doi, Toshihiko
    Sawaki, Akira
    Kanda, Tatsuo
    Yamada, Yasuhide
    Kuss, Iris
    Demetri, George D.
    Nishida, Toshirou
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2015, 20 (05) : 905 - 912
  • [40] Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial
    Yoshito Komatsu
    Toshihiko Doi
    Akira Sawaki
    Tatsuo Kanda
    Yasuhide Yamada
    Iris Kuss
    George D. Demetri
    Toshirou Nishida
    International Journal of Clinical Oncology, 2015, 20 : 905 - 912
12345